Evolent Health, Inc. Logo

Evolent Health, Inc.

EVH

(0.8)
Stock Price

11,15 USD

-11.5% ROA

-6.87% ROE

-39.5x PER

Market Cap.

2.980.512.700,00 USD

74.88% DER

0% Yield

-2.93% NPM

Evolent Health, Inc. Stock Analysis

Evolent Health, Inc. Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Evolent Health, Inc. Fundamental Stock Analysis
# Analysis Rating
1 PBV

The stock's PBV ratio (2.59x) reflects a fair valuation, making it an attractive option for investors seeking balanced opportunities.

2 DER

The stock maintains a fair debt to equity ratio (51%), indicating a reasonable balance between the money it owes and the ownership it possesses.

3 Assets Growth

This company's revenue has shown remarkable growth over the past three years, making it an excellent choice for seeking a consistently prosperous investment.

4 ROE

The stock's ROE indicates a negative return (-9.1%) on shareholders' equity, suggesting poor financial performance.

5 ROA

The stock's ROA (-12.76%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

6 Revenue Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

7 Net Profit Growth

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

8 Graham Number

The Graham number of this company suggests that its stock price may be overvalued, indicating a less favorable investment opportunity.

9 Dividend Growth

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

10 Dividend

The company has not distributed any dividends in the past three years, which may raise concerns for investors looking for regular income from their investments.

11 Buffet Intrinsic Value

The company's stock appears overvalued (-733) by Warren Buffett's formula, suggesting a less favorable investment opportunity as its market price exceeds its estimated intrinsic value.

Evolent Health, Inc. Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Evolent Health, Inc. Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Sell
2 MACD Buy
3 RSI Hold
4 Stoch RSI Sell

Evolent Health, Inc. Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Evolent Health, Inc. Revenue
Year Revenue Growth
2012 8.346.000
2013 25.671.000 67.49%
2014 0 0%
2015 96.878.000 100%
2016 254.188.000 61.89%
2017 434.950.000 41.56%
2018 627.063.000 30.64%
2019 846.383.000 25.91%
2020 1.022.433.000 17.22%
2021 907.957.000 -12.61%
2022 1.352.013.000 32.84%
2023 2.044.060.000 33.86%
2023 1.963.896.000 -4.08%
2024 2.588.580.000 24.13%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Evolent Health, Inc. Research and Development Expenses
Year Research and Development Expenses Growth
2012 0
2013 2.000.000 100%
2014 0 0%
2015 5.800.000 100%
2016 11.100.000 47.75%
2017 17.200.000 35.47%
2018 18.200.000 5.49%
2019 19.800.000 8.08%
2020 15.100.000 -31.13%
2021 15.500.000 2.58%
2022 27.000.000 42.59%
2023 0 0%
2023 26.700.000 100%
2024 0 0%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Evolent Health, Inc. General and Administrative Expenses
Year General and Administrative Expenses Growth
2012 0
2013 15.600.000 100%
2014 0 0%
2015 75.286.000 100%
2016 160.692.000 53.15%
2017 205.670.000 21.87%
2018 306.307.000 32.85%
2019 392.820.000 22.02%
2020 310.551.000 -26.49%
2021 219.499.000 -41.48%
2022 0 0%
2023 0 0%
2023 0 0%
2024 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Evolent Health, Inc. EBITDA
Year EBITDA Growth
2012 -19.505.000
2013 -66.193.000 70.53%
2014 -25.246.000 -162.19%
2015 -449.939.000 94.39%
2016 96.833.000 564.65%
2017 -40.000.000 342.08%
2018 -8.256.000 -384.5%
2019 -65.466.000 87.39%
2020 23.593.000 377.48%
2021 90.285.000 73.87%
2022 7.360.000 -1126.7%
2023 118.164.000 93.77%
2023 46.381.000 -154.77%
2024 161.768.000 71.33%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Evolent Health, Inc. Gross Profit
Year Gross Profit Growth
2012 -2.928.000
2013 -4.347.000 32.64%
2014 0 0%
2015 39.480.000 100%
2016 99.011.000 60.13%
2017 165.598.000 40.21%
2018 299.238.000 44.66%
2019 333.324.000 10.23%
2020 321.060.000 -3.82%
2021 250.406.000 -28.22%
2022 316.584.000 20.9%
2023 497.720.000 36.39%
2023 460.470.000 -8.09%
2024 306.692.000 -50.14%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Evolent Health, Inc. Net Profit
Year Net Profit Growth
2012 -19.263.000
2013 20.023.000 196.2%
2014 -25.246.000 179.31%
2015 332.494.000 107.59%
2016 -159.742.000 308.14%
2017 -60.665.000 -163.32%
2018 -52.658.000 -15.21%
2019 -305.580.000 82.77%
2020 -334.246.000 8.58%
2021 -30.284.000 -1003.7%
2022 -18.701.000 -61.94%
2023 -101.296.000 81.54%
2023 -113.040.000 10.39%
2024 6.384.000 1870.68%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Evolent Health, Inc. Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2012 -1.133
2013 0 0%
2014 -1 0%
2015 13 100%
2016 -4 533.33%
2017 -1 0%
2018 -1 0%
2019 -4 100%
2020 -4 0%
2021 0 0%
2022 0 0%
2023 -1 0%
2023 -1 100%
2024 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Evolent Health, Inc. Free Cashflow
Year Free Cashflow Growth
2012 -15.096.000
2013 -24.067.000 37.28%
2014 -86.128.000 72.06%
2015 -26.344.000 -226.94%
2016 -51.036.000 48.38%
2017 -55.806.000 8.55%
2018 -60.201.000 7.3%
2019 -78.179.000 23%
2020 -45.698.000 -71.08%
2021 13.764.000 432.01%
2022 -49.914.000 127.58%
2023 113.837.000 143.85%
2023 53.728.000 -111.88%
2024 14.311.000 -275.43%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Evolent Health, Inc. Operating Cashflow
Year Operating Cashflow Growth
2012 -12.767.000
2013 -13.629.000 6.32%
2014 -75.094.000 81.85%
2015 -19.829.000 -278.71%
2016 -35.510.000 44.16%
2017 -27.958.000 -27.01%
2018 -20.651.000 -35.38%
2019 -42.645.000 51.57%
2020 -16.225.000 -162.84%
2021 38.747.000 141.87%
2022 -11.553.000 435.38%
2023 142.582.000 108.1%
2023 60.521.000 -135.59%
2024 21.417.000 -182.58%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Evolent Health, Inc. Capital Expenditure
Year Capital Expenditure Growth
2012 2.329.000
2013 10.438.000 77.69%
2014 11.034.000 5.4%
2015 6.515.000 -69.36%
2016 15.526.000 58.04%
2017 27.848.000 44.25%
2018 39.550.000 29.59%
2019 35.534.000 -11.3%
2020 29.473.000 -20.56%
2021 24.983.000 -17.97%
2022 38.361.000 34.87%
2023 28.745.000 -33.45%
2023 6.793.000 -323.16%
2024 7.106.000 4.4%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Evolent Health, Inc. Equity
Year Equity Growth
2012 5.201.000
2013 31.044.000 83.25%
2014 -2.070.000 1599.71%
2015 934.579.000 100.22%
2016 912.114.000 -2.46%
2017 1.046.306.000 12.83%
2018 1.189.356.000 12.03%
2019 929.047.000 -28.02%
2020 619.600.000 -49.94%
2021 693.633.000 10.67%
2022 859.417.000 19.29%
2023 1.067.701.000 19.51%
2023 1.096.093.000 2.59%
2024 1.053.861.000 -4.01%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Evolent Health, Inc. Assets
Year Assets Growth
2012 16.303.999
2013 101.975.000 84.01%
2014 38.277.000 -166.41%
2015 1.015.514.000 96.23%
2016 1.199.839.000 15.36%
2017 1.312.697.000 8.6%
2018 1.722.281.000 23.78%
2019 1.498.015.000 -14.97%
2020 1.370.185.000 -9.33%
2021 1.419.458.000 3.47%
2022 1.817.293.000 21.89%
2023 2.680.308.000 32.2%
2023 2.669.615.000 -0.4%
2024 2.475.109.000 -7.86%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Evolent Health, Inc. Liabilities
Year Liabilities Growth
2012 11.103.000
2013 70.931.000 84.35%
2014 40.347.000 -75.8%
2015 80.935.000 50.15%
2016 287.725.000 71.87%
2017 266.391.000 -8.01%
2018 532.925.000 50.01%
2019 568.968.000 6.33%
2020 750.585.000 24.2%
2021 725.825.000 -3.41%
2022 957.876.000 24.23%
2023 1.612.607.000 40.6%
2023 1.573.522.000 -2.48%
2024 1.421.248.000 -10.71%

Evolent Health, Inc. Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
20.52
Net Income per Share
-0.65
Price to Earning Ratio
-39.5x
Price To Sales Ratio
1.27x
POCF Ratio
16.68
PFCF Ratio
19.75
Price to Book Ratio
2.79
EV to Sales
1.56
EV Over EBITDA
27.86
EV to Operating CashFlow
20.88
EV to FreeCashFlow
24.38
Earnings Yield
-0.03
FreeCashFlow Yield
0.05
Market Cap
2,98 Bil.
Enterprise Value
3,68 Bil.
Graham Number
11.58
Graham NetNet
-8.72

Income Statement Metrics

Net Income per Share
-0.65
Income Quality
-2.37
ROE
-0.07
Return On Assets
-0.03
Return On Capital Employed
-0.01
Net Income per EBT
0.83
EBT Per Ebit
3.9
Ebit per Revenue
-0.01
Effective Tax Rate
0.17

Margins

Sales, General, & Administrative to Revenue
0.11
Research & Developement to Revenue
0.01
Stock Based Compensation to Revenue
0.02
Gross Profit Margin
0.14
Operating Profit Margin
-0.01
Pretax Profit Margin
-0.04
Net Profit Margin
-0.03

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
-0.27
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
1.54
Free CashFlow per Share
1.32
Capex to Operating CashFlow
0.14
Capex to Revenue
0.01
Capex to Depreciation
0.21
Return on Invested Capital
-0.01
Return on Tangible Assets
-0.11
Days Sales Outstanding
57.95
Days Payables Outstanding
7.21
Days of Inventory on Hand
0
Receivables Turnover
6.3
Payables Turnover
50.64
Inventory Turnover
0
Capex per Share
0.22

Balance Sheet

Cash per Share
1,23
Book Value per Share
9,19
Tangible Book Value per Share
-6.75
Shareholders Equity per Share
9.19
Interest Debt per Share
7.22
Debt to Equity
0.75
Debt to Assets
0.32
Net Debt to EBITDA
5.29
Current Ratio
1.08
Tangible Asset Value
-0,77 Bil.
Net Current Asset Value
-0,90 Bil.
Invested Capital
1950627000
Working Capital
0,04 Bil.
Intangibles to Total Assets
0.74
Average Receivables
0,40 Bil.
Average Payables
0,06 Bil.
Average Inventory
0
Debt to Market Cap
0.26

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Evolent Health, Inc. Dividends
Year Dividends Growth

Evolent Health, Inc. Profile

About Evolent Health, Inc.

Evolent Health, Inc., a healthcare company, through its subsidiary, Evolent Health LLC, provides clinical and administrative solutions to payers and providers in the United States. It operates in two segments, Evolent Health Services and Clinical Solutions. The Evolent Health Services segment provides an integrated administrative and clinical platform for health plan administration and population health management. It offers financial and administrative management services, such as health plan services, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients, population health performance that delivers patient-centric cost-effective care. The Clinical Solutions segment offers specialty care management services support a range of specialty care delivery stakeholders during their transition from fee-for-service to value-based care, independent of their stage of maturation and specific market dynamics in oncology and cardiology; and holistic total cost of care improvement. The company was founded in 2011 and is headquartered in Arlington, Virginia.

CEO
Mr. Seth Barrie Blackley
Employee
4.700
Address
800 North Glebe Road
Arlington, 22203

Evolent Health, Inc. Executives & BODs

Evolent Health, Inc. Executives & BODs
# Name Age
1 Mr. Seth Barrie Blackley
Co-Founder, Chief Executive Officer & Director
70
2 Ms. Jessica White
Chief Information Officer
70
3 Mr. Seth R. Frank
Vice President of Investor Relations
70
4 Mr. Dan McCarthy
President
70
5 Mr. John Paul Johnson
Chief Financial Officer
70
6 Ms. Emily Rafferty
Chief Operating Officer
70
7 Mr. Jonathan David Weinberg J.D.
Chief Legal Officer, General Counsel & Secretary
70
8 Mr. Aammaad Shams
Chief Accounting Officer
70
9 Mr. Robert Cruz
Chief Technology Officer
70
10 Mr. Mark Mannion
Senior Vice President of Corporate Finance
70

Evolent Health, Inc. Competitors